Endoluminal Suturing Devices Market Size & Share 2026-2035

Endoluminal Suturing Devices Market Size

The global endoluminal suturing devices market was estimated at USD 81.1 million in 2025. The market is expected to grow from USD 88.7 million in 2026 to USD 290.9 million in 2035, at a CAGR of 14.1% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is driven by numerous factors, such as rising prevalence of chronic disease across the globe and increasing demand for minimally invasive procedures, among other factors.

Endoluminal suturing devices are specialized medical tools designed to place sutures during minimally invasive endoscopic procedures. These devices facilitate internal tissue approximation, repair, and fixation through the gastrointestinal lumen and are commonly used in bariatric surgery, gastroesophageal reflux disease (GERD) treatments, and the management of gastrointestinal perforations or fistulas.

Rising geriatric population is expected to fuel the industry's growth. Boston Scientific, Johnson & Johnson, Medtronic, OLYMPUS, and ovesco are among the leading players operating in the market. These players mainly focus on product innovation, geographic expansion, research and development, and collaboration with local or regional healthcare providers, among other factors.

The market has increased from USD 64.3 million in 2022 and reached USD 74.6 million in 2024, with a historic growth rate of 7.7%. The rising prevalence of chronic diseases globally has significantly contributed to the growth of the endoluminal suturing devices market by increasing the need for minimally invasive gastrointestinal and bariatric interventions. According to the World Health Organization (WHO), approximately 2.5 billion adults were overweight in 2022, of which around 890 million were living with obesity, while 43% of adults were overweight and 16% were obese. Additionally, about 35 million children under the age of 5 were reported to be overweight in 2024. The growing burden of obesity and associated chronic conditions, including gastrointestinal disorders, diabetes, and metabolic diseases, has increased demand for endoluminal procedures, thereby supporting the adoption of advanced suturing devices aimed at improving procedural outcomes and reducing surgical invasiveness.

Additionally, the rising geriatric population has emerged as a key driver supporting the growth of the endoluminal suturing devices market, as aging individuals are more susceptible to gastrointestinal disorders, obesity‑related conditions, and other chronic diseases requiring minimally invasive interventions. According to the World Health Organization (WHO), the global population aged 60 years and above is projected to increase from 1 billion in 2020 to approximately 1.4 billion by 2030, with one in six people expected to be aged 60 years or older. This demographic shift has significantly increased the demand for endoscopic and endoluminal procedures aimed at reducing surgical risks and improving recovery outcomes in elderly patients. Consequently, the growing aging population continues to drive the adoption of advanced suturing devices designed to enhance procedural efficiency, minimize invasiveness, and improve clinical outcomes.

Endoluminal Suturing Devices Market Trends

The technological advancements in endoluminal suturing devices are playing a critical role in driving market growth by enhancing procedural precision, minimally invasive capabilities, and patient safety.

• Modern devices are increasingly incorporating improved tissue acquisition systems, full‑thickness suturing capabilities, and compatibility with standard endoscopes, enabling clinicians to perform complex gastrointestinal interventions without the need for open or laparoscopic surgery. These advancements support a wide range of applications, including defect closure, stent fixation, hemostasis, and bariatric procedures, thereby expanding the clinical utility of endoluminal suturing technologies.
• For instance, the OverStitch Endoscopic Suturing System by Boston Scientific enables full‑thickness suturing and customizable suture patterns, allowing physicians to close defects and perform advanced endoscopic procedures with improved stability and control. Similarly, the OverStitch NXT System offers enhanced compatibility with single‑channel endoscopes, improved flexibility, and physician‑controlled tissue acquisition, enabling access to complex anatomical regions and reducing procedural challenges.
• Product innovations in endoluminal suturing devices emphasize a strong industry focus on precision‑driven, minimally invasive, and patient‑centric solutions, thereby reinforcing technological advancement as a key factor supporting the sustained growth of the market.

Endoluminal Suturing Devices Market Analysis

Based on product type, the global endoluminal suturing devices market is segmented into single use and reusable. The single use segment accounted for a dominant market share of 53.7% in 2025, driven by its ability to ensure enhanced infection control, eliminate cross‑contamination risks, and provide consistent clinical performance across procedures. The segment is expected to reach USD 153.3 million by 2035, growing at a CAGR of 13.9% during the forecast period.

• The single use segment represented the dominating product category in the endoluminal suturing devices market, driven by increasing emphasis on infection control, regulatory compliance, and patient safety. Disposable devices eliminate the risk of cross‑contamination and reduce the need for complex sterilization procedures, supporting consistent performance across therapeutic endoscopic interventions. Growing preference for standardized, hygiene‑focused clinical practices and operational efficiency has further reinforced the adoption of single use endoluminal suturing solutions across healthcare settings.
• The reusable segment is projected to expand at 14.4% CAGR to reach USD 137.6 million by 2035. The reusable segment comprises endoluminal suturing devices designed for repeated use following appropriate sterilization and reprocessing protocols. These systems support cost optimization over multiple procedures and are commonly utilized in established healthcare facilities with advanced sterilization capabilities. Their compatibility with existing endoscopic platforms and ability to deliver reliable performance across a range of gastrointestinal and bariatric procedures continue to support their integration in clinical workflows.

Based on application, the global endoluminal suturing devices market is segmented into gastrointestinal defects, bariatric surgery, gastroesophageal reflux disease, and other applications. The gastrointestinal defects segment is projected to expand at 14.3% CAGR to reach USD 129.3 million by 2035.

• The gastrointestinal defects segment represented the dominating application category in the market, driven by its extensive use in closing perforations, fistulas, and other gastrointestinal tissue defects. Endoluminal suturing devices enable precise tissue approximation, reduce the need for open surgical interventions, and support faster recovery, thereby reinforcing their integration in therapeutic endoscopic procedures.
• The bariatric surgery segment is projected to expand at a 13.7% CAGR to reach USD 94.3 million by 2035. The bariatric surgery segment includes the use of endoluminal suturing devices in procedures such as endoscopic sleeve gastroplasty and revision surgeries aimed at treating obesity. These devices facilitate gastric volume reduction and tissue remodeling through minimally invasive approaches, supporting improved clinical outcomes and reduced procedural risks compared to conventional surgical methods.
• The gastroesophageal reflux disease segment is projected to expand at a 14.8% CAGR to reach USD 48.3 million by 2035. The GERD segment involves the application of endoluminal suturing devices for the reinforcement of the gastroesophageal junction to manage reflux conditions. These devices support effective tissue tightening and restoration of anatomical function, providing a minimally invasive alternative to traditional surgical interventions and improving patient outcomes in chronic reflux management.
• The other applications segment is projected to expand at a 13.3% CAGR to reach USD 19 million by 2035. The other applications segment includes the use of endoluminal suturing devices in procedures such as stent fixation, bleeding control, and post‑surgical defect closure. Their versatility across multiple therapeutic indications supports broader clinical utilization, particularly in complex gastrointestinal interventions requiring precise and minimally invasive tissue management.

Based on end use, the endoluminal suturing devices market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominates the market with a revenue of around USD 48 million in 2025.

• The hospitals segment represented the dominating end‑use category in the market, reflecting the extensive use of these devices in complex gastrointestinal, bariatric, and therapeutic endoscopic procedures performed in hospital settings. The availability of advanced endoscopy suites, multidisciplinary clinical expertise, and access to high‑acuity care supported consistent integration of endoluminal suturing technologies for defect closure, tissue approximation, and minimally invasive interventions.
• The ambulatory surgical centers segment is projected to expand at a 14% CAGR to reach USD 83.9 million by 2035. The ambulatory surgical centers segment includes the use of endoluminal suturing devices in outpatient settings where minimally invasive procedures are performed with reduced hospital stay durations. These centers support efficient workflow management, faster patient throughput, and cost‑effective care delivery, enabling the adoption of suturing devices in selected gastrointestinal and bariatric interventions requiring same‑day discharge.
• The other end users segment is projected to expand at a 13.5% CAGR to reach USD 31.9 million by 2035. The other end users segment comprises specialty clinics and dedicated gastroenterology centers utilizing endoluminal suturing devices for targeted therapeutic applications. These facilities benefit from focused clinical expertise and increasing demand for minimally invasive procedures, supporting the integration of suturing technologies for specialized gastrointestinal and endoscopic treatments.

North America Endoluminal Suturing Devices Market

The North America endoluminal suturing devices industry accounted for a majority share of 36.3% in 2025 and is anticipated to show notable growth over the forecast period.

• The U.S. market was valued at USD 22.5 million and USD 24 million in 2022 and 2023, respectively. The market size reached USD 27.8 million in 2025, growing from USD 25.8 million in 2024, and is anticipated to grow at a CAGR of 13.3% from 2026 to 2035.
• The North America endoluminal suturing devices market was driven by the high burden of obesity and related gastrointestinal and metabolic disorders, which continued to increase the demand for minimally invasive bariatric and therapeutic endoscopic procedures. According to the National Institutes of Health (NIH), approximately 40%–42% of U.S. adults were reported to be living with obesity based on 2017–2023 data, while over 70% were classified as either overweight or obese, with severe obesity rates continuing to rise. This growing prevalence of obesity contributed to higher adoption of endoscopic bariatric therapies, including endoluminal suturing solutions used for gastric volume reduction and revision procedures.
• Additionally, the region benefited from well‑established healthcare infrastructure, advanced clinical expertise, and early adoption of innovative endoscopic technologies. Increasing focus on reducing hospital stays, improving patient outcomes, and shifting toward minimally invasive treatment approaches supported the integration of advanced suturing devices across gastroenterology practices. Strong presence of key market players and continuous product innovation further reinforced North America’s position as a leading market for endoluminal suturing devices.

Europe Endoluminal Suturing Devices Market

Europe accounted for a significant share of the endoluminal suturing devices industry and was valued at USD 20.8 million in 2025.

• The Europe market was supported by the growing geriatric population and the increasing burden of age‑related gastrointestinal and metabolic disorders across the region. According to Eurostat, the EU population was estimated at approximately 450.6 million in January 2025, with more than 22% aged 65 years and over, reflecting a significant aging demographic profile. This shift toward an older population increased the prevalence of conditions such as obesity‑related complications, gastrointestinal disorders, and post‑surgical revisions, thereby strengthening demand for minimally invasive therapeutic solutions, including endoluminal suturing devices.
• Furthermore, the presence of advanced healthcare systems and strong adoption of endoscopic technologies supported market growth. European healthcare providers increasingly prioritized minimally invasive and cost‑efficient treatment approaches, leading to greater utilization of endoluminal suturing devices for gastric remodeling, defect closure, and complex therapeutic procedures. Continued investment in medical innovation, along with favorable clinical practices and a growing focus on improving patient outcomes in elderly populations, further supported the expansion of the market across Europe.

Asia Pacific Endoluminal Suturing Devices Market

The Asia Pacific endoluminal suturing devices industry accounted for a substantial share of the market and was valued at USD 14.9 million in 2025.

• The Asia Pacific market was increasingly supported by rapid demographic aging across the region, which significantly expanded the patient population requiring minimally invasive gastrointestinal and bariatric interventions. According to the United Nations Population Fund (UNFPA), by 2050, one in four people in Asia and the Pacific was projected to be aged over 60 years, with the older population expected to nearly triple between 2010 and 2050, reaching close to 1.3 billion individuals. This demographic transition contributed to a higher incidence of age‑related gastrointestinal disorders, metabolic diseases, and surgical complications, thereby increasing the demand for advanced endoluminal suturing solutions.
• Combined with rising healthcare investments, expanding specialist training, and increasing accessibility to advanced medical technologies, these factors positioned Asia Pacific as a key growth region in the market.

Latin America Endoluminal Suturing Devices Market

The Latin America endoluminal suturing devices industry is anticipated to exhibit remarkable growth during the analysis period.

• The Latin America market was influenced by the increasing adoption of bariatric and advanced gastrointestinal procedures across the region, supported by rising procedural volumes and improving access to specialized care. According to the International Federation for the Surgery of Obesity (IFSO) Worldwide Survey 2020–2021, the Latin America Chapter reported approximately 104,239 surgical and endoluminal procedures in 2021, highlighting the growing utilization of minimally invasive techniques for obesity and metabolic disorder management. This procedural expansion reinforced the demand for endoluminal suturing devices, particularly in applications such as gastric remodeling, revision procedures, and defect closure.
• Additionally, expansion of private healthcare services and increasing patient awareness regarding minimally invasive treatment options further supported the growth trajectory of the market in Latin America.

Middle East and Africa Endoluminal Suturing Devices Market

The Middle East and Africa endoluminal suturing devices industry is expected to experience substantial growth over the analysis timeframe.

• The Middle East and Africa market has been influenced by the rising burden of obesity and metabolic disorders across the region, which has increased the demand for minimally invasive gastrointestinal and bariatric procedures. The growing prevalence of lifestyle‑related conditions, particularly in urban populations, has contributed to higher adoption of advanced endoscopic techniques aimed at improving treatment outcomes while reducing procedural risks.
• The increasing presence of advanced medical facilities and gradual adoption of innovative therapeutic technologies have enabled healthcare providers to incorporate endoluminal suturing solutions into clinical practice, thereby supporting steady market growth across the MEA region.

Endoluminal Suturing Devices Market Share

• The endoluminal suturing devices industry is highly dynamic, with key players such as Boston Scientific, Johnson & Johnson, Medtronic, OLYMPUS, and Ovesco, which collectively account for 70% of the global market.

• These companies leverage comprehensive endoscopy portfolios and integrated procedural solutions that include advanced suturing platforms, endoscopic access systems, and imaging‑compatible technologies. Their strategic strength lies in enabling complex gastrointestinal interventions through standardized devices, structured clinician training programs, and optimized endoscopic workflows, thereby improving procedural efficiency, reducing invasiveness, and enhancing clinical outcomes across minimally invasive therapeutic applications.
• Concurrently, emerging and regional manufacturers are strengthening their market presence by offering cost‑effective and procedure‑specific endoluminal suturing solutions tailored to regional healthcare requirements. Innovation within the competitive landscape is centered on advancements in device design, including improved maneuverability, full‑thickness suturing capability, and compatibility with standard endoscopes. Strategic partnerships, technology collaborations, and targeted mergers and acquisitions continue to play a critical role as companies seek to expand geographic presence, enhance product portfolios, and differentiate within the evolving market.

Endoluminal Suturing Devices Market Companies

A few of the prominent players operating in the endoluminal suturing devices industry include:

• B. Braun       
• Boston Scientific      
• Cook Group  
• Endo Tools Therapeutics     
• ergosuture    
• Johnson & Johnson  
• Karl Storz     
• LUMENDi       
• Medtronic     
• OLYMPUS      
• Ovesco         
• RICHARD WOLF       
• Teleflex        
• Terumo         
• USGI MEDICAL        
• Boston Scientific

Boston Scientific has established a leading position in the endoluminal suturing devices market through its comprehensive endoscopy portfolio, strengthened by the acquisition of Apollo Endosurgery and its OverStitch suturing platform. The company focuses on advancing endoluminal surgery (ELS) by enabling minimally invasive gastrointestinal interventions, including defect closure and bariatric procedures. Its strong global distribution network, integration of suturing systems with endoscopic platforms, and emphasis on clinical training and procedural standardization continue to support widespread adoption across gastroenterology practices.

• Johnson & Johnson

Johnson & Johnson, through its Ethicon division, maintains a strong presence in the endoluminal suturing devices market by leveraging its extensive expertise in surgical suturing and minimally invasive technologies. While primarily focused on traditional and laparoscopic suturing solutions, the company supports endoluminal applications through advanced surgical instrumentation and innovation in tissue closure technologies. Its global brand strength, established relationships with healthcare providers, and continued investments in minimally invasive surgery enable its participation in the evolving endoscopic suturing landscape.

• Medtronic

Medtronic plays a significant role in the endoluminal suturing devices market through its broad gastrointestinal and minimally invasive therapy portfolio. Although its presence is more indirect compared to dedicated suturing system providers, the company supports endoluminal procedures with advanced endoscopy tools, access devices, and surgical platforms. Medtronic’s focus on innovation, integration of surgical technologies, and expansion of minimally invasive treatment solutions continues to strengthen its involvement in therapeutic endoscopy and related procedural ecosystems.

The endoluminal suturing devices market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Single use
• Reusable

Market, By Application

• Gastrointestinal defects
• Bariatric surgery
• Gastroesophageal reflux disease (GERD)
• Other applications

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE